{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-23-000055","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.084496+00:00","generated_at":"2026-06-08T08:36:23.604829+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexicon Q3 net loss $50.5M ($0.21/sh); INPEFA revenue $0.4M since launch","bullets":["Net loss of $50.5M vs $23.4M a year ago; loss per share $0.21 vs $0.13.","Total Q3 revenue $0.2M; INPEFA net product revenues since June launch total $0.4M.","Express Scripts placed INPEFA on Premier Access, Premier Performance (Medicare) and Basic/High Performance (commercial) formularies effective Nov 1.","LX9211 Phase 2b enrollment expected to begin in December 2023 for diabetic peripheral neuropathic pain.","Cash and investments $218.4M as of Sept 30, 2023, up from $138.4M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-23-000055","json":"https://secwatch.observer/filing/0001062822-23-000055.json","markdown":"https://secwatch.observer/filing/0001062822-23-000055.md","text":"https://secwatch.observer/filing/0001062822-23-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000055/0001062822-23-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000055/lxrx-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:36:23.604829+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}